Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Landiolol (also known as LDLL600 and ONO 1101) is a beta1 selective, ultra-short-acting β1-adrenergic blocker which is useful for managing supraventricular tachyarrhythmias in sepsis. The medication landiolol functions as an extremely short-acting, highly cardioselective beta blocker. It functions as an anti-arrhythmic medication. Landiolol reduces hemodynamic responses to bronchoscopy-assisted suctioning in intubated ICU patients.
Targets |
beta-adrenergic receptor
|
---|---|
References |
|
Molecular Formula |
C25H40CLN3O8
|
---|---|
Molecular Weight |
546.0534
|
Exact Mass |
545.25
|
Elemental Analysis |
C, 54.99; H, 7.38; Cl, 6.49; N, 7.70; O, 23.44
|
CAS # |
144481-98-1
|
Related CAS # |
144481-98-1 (HCl); 33242-30-5
|
Appearance |
Solid powder
|
SMILES |
CC1(OC[C@H](O1)COC(=O)CCC2=CC=C(C=C2)OC[C@H](CNCCNC(=O)N3CCOCC3)O)C.Cl
|
InChi Key |
DLPGJHSONYLBKP-IKGOIYPNSA-N
|
InChi Code |
InChI=1S/C25H39N3O8.ClH/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28;/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31);1H/t20-,22+;/m0./s1
|
Chemical Name |
[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate;hydrochloride
|
Synonyms |
ONO1101; ONO-1101; ONO 1101 hydrochloride; LDLL600; LDLL 600; LDLL-600; Landiolol; Landiolol HCl; Landiolol hydrochloride
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100~250 mg/mL (183.1~457.8 mM)
Water: ~100 mg/mL Ethanol: ~42 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8313 mL | 9.1567 mL | 18.3133 mL | |
5 mM | 0.3663 mL | 1.8313 mL | 3.6627 mL | |
10 mM | 0.1831 mL | 0.9157 mL | 1.8313 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05084118 | Recruiting | Drug: Landiolol HCl Drug: Placebo |
Postoperative Complications Atrial Fibrillation |
Medical University of Vienna | October 21, 2021 | Phase 3 |
NCT03779178 | Completed | Drug: Landiolol Drug: Placebo |
Atrial Fibrillation | Hospices Civils de Lyon | January 17, 2019 | Phase 3 |
NCT00311038 | Completed | Drug: ONO-1101 | Coronary Artery Disease | Ono Pharmaceutical Co. Ltd | April 2006 | Phase 2 |
NCT00212680 | Completed | Drug: ONO-1101 | Postoperative Supraventricular Tachyarrythmia |
Ono Pharma USA Inc | April 2006 | Phase 2 |
NCT00212654 | Completed | Drug: ONO-1101 | Postoperative Supraventricular Tachyarrythmia |
Ono Pharmaceutical Co. Ltd | June 2001 | Phase 2 Phase 3 |